MEDI7247

Overview

An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against an unnamed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of MEDI7247 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.

SparkCures ID 278
Developed By MedImmune
Generic Name MEDI7247
Treatment Classifications

Clinical Trials

Resources

There are no resources, links or videos to display for this treatment.